SG10201913263SA - Heterodimeric immunoglobulin constructs and preparation methods thereof - Google Patents
Heterodimeric immunoglobulin constructs and preparation methods thereofInfo
- Publication number
- SG10201913263SA SG10201913263SA SG10201913263SA SG10201913263SA SG10201913263SA SG 10201913263S A SG10201913263S A SG 10201913263SA SG 10201913263S A SG10201913263S A SG 10201913263SA SG 10201913263S A SG10201913263S A SG 10201913263SA SG 10201913263S A SG10201913263S A SG 10201913263SA
- Authority
- SG
- Singapore
- Prior art keywords
- preparation methods
- heterodimeric immunoglobulin
- immunoglobulin constructs
- constructs
- heterodimeric
- Prior art date
Links
- 108060003951 Immunoglobulin Proteins 0.000 title 1
- 102000018358 immunoglobulin Human genes 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/66—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610863814 | 2016-09-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201913263SA true SG10201913263SA (en) | 2020-03-30 |
Family
ID=61762488
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201901307VA SG11201901307VA (en) | 2016-09-29 | 2017-09-28 | Heterodimeric immunoglobulin constructs and preparation methods thereof |
| SG10201913263SA SG10201913263SA (en) | 2016-09-29 | 2017-09-28 | Heterodimeric immunoglobulin constructs and preparation methods thereof |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201901307VA SG11201901307VA (en) | 2016-09-29 | 2017-09-28 | Heterodimeric immunoglobulin constructs and preparation methods thereof |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US11498977B2 (en) |
| EP (1) | EP3504234A4 (en) |
| JP (1) | JP7424727B2 (en) |
| KR (1) | KR102242990B1 (en) |
| CN (1) | CN109790215B (en) |
| AU (1) | AU2017336867B2 (en) |
| BR (1) | BR112019006074A2 (en) |
| CA (1) | CA3035681A1 (en) |
| CL (1) | CL2019000836A1 (en) |
| CO (1) | CO2019003133A2 (en) |
| DO (1) | DOP2019000079A (en) |
| EA (1) | EA201990285A1 (en) |
| EC (1) | ECSP19022190A (en) |
| IL (1) | IL265605B1 (en) |
| MX (1) | MX2019003563A (en) |
| MY (1) | MY194994A (en) |
| PE (1) | PE20190576A1 (en) |
| PH (1) | PH12019500655A1 (en) |
| SA (1) | SA519401441B1 (en) |
| SG (2) | SG11201901307VA (en) |
| TN (1) | TN2019000055A1 (en) |
| WO (1) | WO2018059502A1 (en) |
| ZA (1) | ZA201901708B (en) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018090950A1 (en) | 2016-11-18 | 2018-05-24 | 北京韩美药品有限公司 | Anti-pd-1/anti-her2 natural antibody structure-like bispecific antibody of heterodimeric form and preparation thereof |
| EA201992311A1 (en) | 2017-04-01 | 2020-05-15 | Бэйцзин Ханми Фарм. Ко., Лтд. | HETERODIMERIC BESPECIFIC ANTIBODY TO PD-L1 / PD-1 WITH A STRUCTURE SIMILAR TO NATURAL ANTIBODY AND ITS OBTAINING |
| MX2020005792A (en) * | 2017-12-04 | 2020-11-06 | Beijing Hanmi Pharmaceutical Co Ltd | Anti-pd-l1/anti-cd47 bispecific antibody with structure like natural antibody and in form of heterodimer and preparation thereof. |
| WO2019153200A1 (en) | 2018-02-08 | 2019-08-15 | 北京韩美药品有限公司 | Anti-pd-1/anti-her2 natural antibody structure-like bispecific antibody in heterodimeric form and preparation thereof |
| US11827697B2 (en) | 2018-02-11 | 2023-11-28 | Beijing Hanmi Pharmaceutical Co., Ltd. | Anti-PD-1/anti-VEGF natural antibody structure like heterodimeric form bispecific antibody and preparation thereof |
| US20210139582A1 (en) * | 2018-02-13 | 2021-05-13 | The Brigham And Women's Hospital, Inc. | Therapeutic fcrn-based bispecific monoclonal antibodies |
| EP3878870A4 (en) * | 2018-11-05 | 2022-08-03 | Beijing Hanmi Pharmaceutical Co., Ltd. | ANTI-TNFa/ANTI IL-17A NATURAL ANTIBODY STRUCTURE-LIKE HETERODIMER FORM OF BISPECIFIC ANTIBODY AND PREPARATION METHOD THEREFOR |
| WO2020232247A1 (en) | 2019-05-14 | 2020-11-19 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
| CN113121697B (en) * | 2019-12-31 | 2023-06-09 | 周易 | CH3 domain modification induced heterodimer and preparation method and application thereof |
| US20240092931A1 (en) * | 2020-08-24 | 2024-03-21 | Janux Therapeutics, Inc. | Antibodies targeting trop2 and cd3 and uses thereof |
| JP2024503393A (en) * | 2021-01-08 | 2024-01-25 | 北京韓美薬品有限公司 | Anti-PD-L1/anti-4-1BB natural antibody structure-like heterodimer bispecific antibody and method for producing the same |
| KR20230147092A (en) * | 2021-01-22 | 2023-10-20 | 바이원큐어 테라퓨틱스, 인크. | Anti-HER-2/TROP-2 constructs and uses thereof |
| KR20230060546A (en) | 2021-10-22 | 2023-05-04 | 상트네어바이오사이언스 주식회사 | ANTIGEN BINDING PROTEINS WITH TWO Fc DOMAINS AND USE THEREOF |
| CN114539420B (en) * | 2022-01-20 | 2024-05-17 | 荣昌生物制药(烟台)股份有限公司 | Anti-B7-H3 monoclonal antibody, anti-B7-H3 xCD 3 bispecific antibody, preparation method and application thereof |
| WO2023143343A1 (en) * | 2022-01-26 | 2023-08-03 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Anti-her2/trop2 antibodies and uses thereof |
| WO2023164640A1 (en) * | 2022-02-24 | 2023-08-31 | Xencor, Inc. | Anti-cd28 x anti-trop2 antibodies |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL9100352A (en) | 1991-02-27 | 1992-09-16 | Hoogovens Groep Bv | METHOD FOR MANUFACTURING IRON FOIL BY ELECTRODE POSITION. |
| DE4429450A1 (en) * | 1993-08-25 | 1995-03-02 | Osberger Helmut Jun | Yeast/fresh cell/enzyme beverage |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| DE69936946T2 (en) | 1998-05-06 | 2008-05-15 | Genentech, Inc., South San Francisco | Purification of antibodies by ion exchange chromatography |
| US20050106667A1 (en) | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
| US20060074225A1 (en) | 2004-09-14 | 2006-04-06 | Xencor, Inc. | Monomeric immunoglobulin Fc domains |
| DK2170959T3 (en) | 2007-06-18 | 2014-01-13 | Merck Sharp & Dohme | ANTIBODIES AGAINST HUMAN PROGRAMMED DEATH RECEPTOR PD-1 |
| PL2235064T3 (en) | 2008-01-07 | 2016-06-30 | Amgen Inc | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
| SG175233A1 (en) * | 2009-04-22 | 2011-11-28 | Merck Patent Gmbh | Antibody fusion proteins with modified fcrn binding sites |
| EP2504360B1 (en) | 2009-11-23 | 2018-08-15 | Amgen Inc. | Monomeric antibody fc |
| CN103429620B (en) | 2010-11-05 | 2018-03-06 | 酵活有限公司 | There is the antibody design of the stable heterodimeric of mutation in Fc domains |
| CN108285488B (en) | 2011-03-25 | 2023-01-24 | 伊克诺斯科学公司 | Heterodimeric immunoglobulins |
| RU2625034C2 (en) | 2011-04-20 | 2017-07-11 | МЕДИММЬЮН, ЭлЭлСи | Antibodies and other molecules binding b7-h1 and pd-1 |
| US10344050B2 (en) | 2011-10-27 | 2019-07-09 | Genmab A/S | Production of heterodimeric proteins |
| WO2014067011A1 (en) * | 2012-11-02 | 2014-05-08 | Zymeworks Inc. | Crystal structures of heterodimeric fc domains |
| KR102052774B1 (en) | 2011-11-04 | 2019-12-04 | 자임워크스 인코포레이티드 | Stable heterodimeric antibody design with mutations in the fc domain |
| PT2838917T (en) | 2012-04-20 | 2019-09-12 | Merus Nv | Methods and means for the production of heterodimeric ig-like molecules |
| AU2013322710A1 (en) * | 2012-09-25 | 2015-04-16 | Glenmark Pharmaceuticals S.A. | Purification of hetero-dimeric immunoglobulins |
| CA2893562C (en) | 2012-11-28 | 2023-09-12 | Zymeworks Inc. | Engineered immunoglobulin heavy chain-light chain pairs and uses thereof |
| US9914785B2 (en) | 2012-11-28 | 2018-03-13 | Zymeworks Inc. | Engineered immunoglobulin heavy chain-light chain pairs and uses thereof |
| ES2784631T3 (en) | 2012-12-03 | 2020-09-29 | Novimmune Sa | Anti-CD47 antibodies and methods of using them |
| RU2705795C2 (en) | 2013-08-20 | 2019-11-12 | Мерк Шарп И Доум Корп. | Treating cancer with combination of pd-1 antagonist and dinaciclib |
| EP3083686B2 (en) | 2013-12-17 | 2023-03-22 | F. Hoffmann-La Roche AG | Methods of treating cancers using pd-1 axis binding antagonists and taxanes |
| WO2015095412A1 (en) | 2013-12-19 | 2015-06-25 | Zhong Wang | Bispecific antibody with two single-domain antigen-binding fragments |
| TWI681969B (en) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | Human antibodies to pd-1 |
| JOP20200094A1 (en) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | Antibody molecules to pd-1 and uses thereof |
| ES2751915T5 (en) | 2014-08-15 | 2022-12-23 | Merck Patent Gmbh | Immunoglobulin fusion proteins with SIRP alpha |
| WO2016057933A1 (en) | 2014-10-10 | 2016-04-14 | Global Biopharma, Inc. | Methods for treating and/or preventing a tumor growth, invasion and/or metastasis |
| WO2016109415A1 (en) | 2014-12-30 | 2016-07-07 | Celgene Corporation | Anti-cd47 antibodies and uses thereof |
| CN107614522A (en) | 2015-01-14 | 2018-01-19 | 指南针制药有限责任公司 | Multispecific immune modulability antigen-binding constructs |
| WO2016170039A1 (en) | 2015-04-23 | 2016-10-27 | F. Hoffmann-La Roche Ag | Combination therapy of antibody binding to angiopoietin 2 with antibody binding to programmed death 1 polypeptide |
| TW201709929A (en) | 2015-06-12 | 2017-03-16 | 宏觀基因股份有限公司 | Combination therapy for the treatment of cancer |
| CN105111314B (en) | 2015-08-13 | 2019-01-08 | 成都百世博生物技术有限公司 | A kind of new fusion protein, pharmaceutical composition and its preparation method and application |
| CN105175545B (en) | 2015-10-20 | 2019-01-25 | 安徽瀚海博兴生物技术有限公司 | A kind of anti-PD-1 bifunctional antibody of anti-vegf-and its application |
| CN106883297B (en) | 2015-12-16 | 2019-12-13 | 苏州康宁杰瑞生物科技有限公司 | CH3 domain-based heterodimer molecule, preparation method and application thereof |
| US11459405B2 (en) | 2015-12-28 | 2022-10-04 | Massachusetts Institute Of Technology | Bispecific antibodies having constant region mutations and uses therefor |
| WO2017167350A1 (en) | 2016-03-30 | 2017-10-05 | Horst Lindhofer | Multispecific antibodies for use in the treatment of a neoplasm of the urinary tract |
| GB201611530D0 (en) | 2016-07-01 | 2016-08-17 | Alligator Bioscience Ab | Novel polypeptides |
| JP6967515B2 (en) | 2016-10-15 | 2021-11-17 | イノベント バイオロジックス （スウツォウ） カンパニー，リミテッド | PD-1 antibody |
| WO2018090950A1 (en) * | 2016-11-18 | 2018-05-24 | 北京韩美药品有限公司 | Anti-pd-1/anti-her2 natural antibody structure-like bispecific antibody of heterodimeric form and preparation thereof |
| EA201992311A1 (en) * | 2017-04-01 | 2020-05-15 | Бэйцзин Ханми Фарм. Ко., Лтд. | HETERODIMERIC BESPECIFIC ANTIBODY TO PD-L1 / PD-1 WITH A STRUCTURE SIMILAR TO NATURAL ANTIBODY AND ITS OBTAINING |
| AR112603A1 (en) | 2017-07-10 | 2019-11-20 | Lilly Co Eli | BIS SPECIFIC ANTIBODIES CONTROL POINT INHIBITORS |
| CN107325184A (en) | 2017-08-08 | 2017-11-07 | 安徽大学 | The bispecific antibody of a kind of targeting EGFR and HER2 and its application |
| EA039662B1 (en) | 2017-10-03 | 2022-02-24 | Закрытое Акционерное Общество "Биокад" | Antibodies specific to cd47 and pd-l1 |
| MX2020005792A (en) * | 2017-12-04 | 2020-11-06 | Beijing Hanmi Pharmaceutical Co Ltd | Anti-pd-l1/anti-cd47 bispecific antibody with structure like natural antibody and in form of heterodimer and preparation thereof. |
| WO2019153200A1 (en) * | 2018-02-08 | 2019-08-15 | 北京韩美药品有限公司 | Anti-pd-1/anti-her2 natural antibody structure-like bispecific antibody in heterodimeric form and preparation thereof |
| US11827697B2 (en) * | 2018-02-11 | 2023-11-28 | Beijing Hanmi Pharmaceutical Co., Ltd. | Anti-PD-1/anti-VEGF natural antibody structure like heterodimeric form bispecific antibody and preparation thereof |
| EP3878870A4 (en) * | 2018-11-05 | 2022-08-03 | Beijing Hanmi Pharmaceutical Co., Ltd. | ANTI-TNFa/ANTI IL-17A NATURAL ANTIBODY STRUCTURE-LIKE HETERODIMER FORM OF BISPECIFIC ANTIBODY AND PREPARATION METHOD THEREFOR |
-
2017
- 2017-09-28 JP JP2019516702A patent/JP7424727B2/en active Active
- 2017-09-28 IL IL265605A patent/IL265605B1/en unknown
- 2017-09-28 EA EA201990285A patent/EA201990285A1/en unknown
- 2017-09-28 SG SG11201901307VA patent/SG11201901307VA/en unknown
- 2017-09-28 EP EP17854952.3A patent/EP3504234A4/en active Pending
- 2017-09-28 SG SG10201913263SA patent/SG10201913263SA/en unknown
- 2017-09-28 AU AU2017336867A patent/AU2017336867B2/en active Active
- 2017-09-28 PE PE2019000733A patent/PE20190576A1/en unknown
- 2017-09-28 CA CA3035681A patent/CA3035681A1/en active Pending
- 2017-09-28 WO PCT/CN2017/104044 patent/WO2018059502A1/en unknown
- 2017-09-28 KR KR1020197009091A patent/KR102242990B1/en active IP Right Grant
- 2017-09-28 BR BR112019006074A patent/BR112019006074A2/en unknown
- 2017-09-28 MX MX2019003563A patent/MX2019003563A/en unknown
- 2017-09-28 CN CN201780060756.7A patent/CN109790215B/en active Active
- 2017-09-28 TN TNP/2019/000055A patent/TN2019000055A1/en unknown
- 2017-09-28 MY MYPI2019001672A patent/MY194994A/en unknown
- 2017-09-28 US US16/337,854 patent/US11498977B2/en active Active
-
2019
- 2019-03-19 ZA ZA2019/01708A patent/ZA201901708B/en unknown
- 2019-03-26 PH PH12019500655A patent/PH12019500655A1/en unknown
- 2019-03-28 CL CL2019000836A patent/CL2019000836A1/en unknown
- 2019-03-28 DO DO2019000079A patent/DOP2019000079A/en unknown
- 2019-03-28 SA SA519401441A patent/SA519401441B1/en unknown
- 2019-03-29 EC ECSENADI201922190A patent/ECSP19022190A/en unknown
- 2019-03-29 CO CONC2019/0003133A patent/CO2019003133A2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019535650A (en) | 2019-12-12 |
| CL2019000836A1 (en) | 2019-08-02 |
| SA519401441B1 (en) | 2022-12-27 |
| CN109790215A (en) | 2019-05-21 |
| IL265605A (en) | 2019-05-30 |
| BR112019006074A2 (en) | 2019-06-18 |
| KR20190055813A (en) | 2019-05-23 |
| US11498977B2 (en) | 2022-11-15 |
| ECSP19022190A (en) | 2019-05-31 |
| AU2017336867A1 (en) | 2019-02-28 |
| MX2019003563A (en) | 2019-08-12 |
| JP7424727B2 (en) | 2024-01-30 |
| IL265605B1 (en) | 2024-02-01 |
| MY194994A (en) | 2022-12-30 |
| PH12019500655A1 (en) | 2019-08-05 |
| SG11201901307VA (en) | 2019-03-28 |
| US20190284299A1 (en) | 2019-09-19 |
| TN2019000055A1 (en) | 2020-07-15 |
| EP3504234A4 (en) | 2020-12-02 |
| DOP2019000079A (en) | 2019-11-15 |
| CO2019003133A2 (en) | 2019-04-12 |
| PE20190576A1 (en) | 2019-04-22 |
| AU2017336867B2 (en) | 2024-03-14 |
| CN109790215B (en) | 2023-06-30 |
| ZA201901708B (en) | 2022-11-30 |
| EP3504234A1 (en) | 2019-07-03 |
| KR102242990B1 (en) | 2021-04-22 |
| CA3035681A1 (en) | 2018-04-05 |
| EA201990285A1 (en) | 2019-12-30 |
| WO2018059502A1 (en) | 2018-04-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL265605A (en) | Heterodimeric immunoglobulin constructs and preparation methods thereof | |
| HK1258274A1 (en) | Antibody/t-cell receptor chimeric constructs and uses thereof | |
| HK1248251A1 (en) | Antibody constructs for flt3 and cd3 | |
| IL260937A (en) | Fabs-in-tandem immunoglobulin and uses thereof | |
| HK1249405A1 (en) | Anti-dll3 chimeric antigen receptors and methods of use | |
| IL255336A0 (en) | Chimeric antigen receptors and methods of their use | |
| IL263223A (en) | Anti-cd40 antibodies and their uses | |
| HK1251969A1 (en) | Anti-her2 antibodies and methods of use | |
| EP3259352A4 (en) | Chimeric antigen receptors and uses thereof | |
| IL276515A (en) | Pd-l1-specific antibodies and methods of using the same | |
| EP3347474A4 (en) | Chimeric antigen receptors and uses thereof | |
| IL266143A (en) | Antibody constructs | |
| HK1256816A1 (en) | Novel anti-human gpvi antibodies and uses thereof | |
| GB201810451D0 (en) | Anti-placenta-chondroitin-sulfate chimeric antigen receptor and application thereof | |
| HK1251456A1 (en) | Immunoglobulin fusion proteins and uses thereof | |
| GB201615335D0 (en) | Antibodies and immunocytokines |